MétaCan
Menu
Back to cohort

853 Design of a next generation tumor targeted masked IL-12Fc for enhanced tolerability and localized anti-tumor activity

2025· article· W4415899041 on OpenAlexaff
Nichole Escalante, Sifa Arrafi, Andrew J Sharon, Minasadat Khoddami, Gavin Storoschuk, Alexia Piercey, Polly Shao, Larissa Patlan, Scott Lien, Catherine H. Wu, R. Kunze, Maya C. Poffenberger, Chayne L. Piscitelli, Paul A. Moore, Nina E. Weisser, A. A. Berezhnoy, Thomas Spreter von Kreudenstein

Bibliographic record

VenueRegular and Young Investigator Award Abstracts · 2025
Typearticle
Language
FieldMedicine
TopicMonoclonal and Polyclonal Antibodies Research
Canadian institutionsZymeworks (Canada)
Fundersnot available
KeywordsTolerabilityTumor cellsClinical trialContext (archaeology)Solid tumor

Abstract

fetched live from OpenAlex

Background IL-12 is a potent immunostimulatory cytokine whose use as an anti-tumor therapeutic has been limited by severe toxicities associated with systemic administration. Tumor targeting and conditional activation in the tumor microenvironment (TME) are two alternative, potentially complementary, strategies to increase therapeutic index of cytokines. To improve the pharmacokinetics and tolerability of IL-12, we have engineered a masked, protease activated human IL-12Fc with attenuated potency (ZW270). ZW270 is engineered with an internally developed, highly efficient cleavage sequence to provide conditional activation of IL-12Fc in a protease-rich tumor environment. Previous data has shown efficient masking of IL-12Fc activity, improved pharmacokinetics and an expanded therapeutic index of ZW270 in vivo compared to wild type IL-12Fc. ZW270 was well tolerated in non-human primates (>30mg/kg) with slow extended release in the serum.1 While this data demonstrates the benefits of the above combined strategies, additional benefit could be gained by targeting ZW270 to the tumor environment, increasing retention time and further localizing IL-12 activity.Methods To delineate the advantages of targeting a conditionally masked IL-12Fc to the tumor environment, with a tumor targeting Fab, we developed a surrogate masked, protease activated, potency attenuated, mouse IL-12Fc, mZW270. The potency, efficacy and tolerability of a targeted mZW270 was evaluated in vitro and in syngeneic tumor models.Results Targeted mZW270 demonstrated efficient masking and attenuated potency, similar to ZW270, in in vitro splenocyte and reporter gene assays. In vivo, compared to wild type mouse IL-12Fc (no masking, attenuation or targeting), it was better tolerated with no early severe bodyweight loss, highlighting the advantage of combined masking and attenuation strategies. In syngeneic and transgenic models, with varying tumor antigen densities, targeted mZW270 activated a local tumor immune response, leading to strong anti-tumor activity, lowering the minimum effective dose without decreasing the tolerability. Initial characterization of a targeted ZW270 indicated translatability of these observations to a human therapeutic.Conclusions Overall, our combined strategies of masking, potency attenuation and tumor targeting can be incorporated to widen the therapeutic index of an IL-12 based therapeutic.Reference Poffenber, et al. ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity. Cancer Res. 2023;83(7_Supplement):2935. https://doi.org/10.1158/1538-7445.AM2023-2935. AACR 2023

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.055
GPT teacher head0.307
Teacher spread0.252 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractno

Explore more

Same venueRegular and Young Investigator Award AbstractsSame topicMonoclonal and Polyclonal Antibodies ResearchFrench-language works237,207